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Background: Interleukin-10 (IL-10) is an important immunoregulatory cytokine.
There are few studies evaluating the association between IL-10 and lupus nephritis
(LN). The aim of this study was to evaluate the association of IL-10 gene promoter
-592 A/C with LN susceptibility.
Methods: The study was conducted on 84 patients with systemic lupus erythe-
matosus (SLE). Patients were divided into LN group (Group I, 48 patients) and non-
LN group (Group II, 36 patients). The -592 A/C polymorphisms in IL-10 promoter
gene were determined by polymerase chain reaction and restriction fragment
length polymorphism in both groups. IL-10 was determined by enzyme-linked
immunosorbent assay. Frequencies of the genotypes were compared between LN
and non-LN patients and among LN patients with different pathologic classes.
Results: There was a signiﬁcant increase in serum level of IL-10 (P ¼ 0.001) in
Group I compared with Group II and signiﬁcant positive correlation between serum
IL-10 and SLE disease activity index (r ¼ 0.466, P ¼ 0.001) in Group I. There were no
signiﬁcant differences in the distribution of the IL-10 gene promoter -592 A/C ge-
notypes or the allele frequencies between Groups I and II. There was no signiﬁcant
difference between AC/CC and AA genotypes with SLE disease activity index, pro-
teinuria, hematuria, anti-double-stranded DNA, and IL-10 in Group I. There was no
signiﬁcant difference in the distribution of AC and CC genotypes among different
pathologic LN classes.
Conclusion: IL-10 suggested to play a role in pathogenesis and development of LN.
However, the promoter -592 A/C of IL-10 gene suggested to be not associated with
serum IL-10 levels or LN susceptibility. In addition, it appears that promoter -592 A/C
of IL-10 gene not associated with LN activity or the pathologic classes of LN.
Copyright © 2016. The Korean Society of Nephrology. Published by Elsevier. This is
an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).search Institute, El-Nile
iza 12411, Egypt.
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ty of Nephrology. Published b
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Systemic lupus erythematosus (SLE) is a multisystem
autoimmune disease. Many factors are associated with
the development of the SLE, including genetic, ethnic,
immunoregulatory, hormonal, and environmental factors
[1e4].y Elsevier. This is an open access article under the CC BY-NC-ND license
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by that SLE is more common in ﬁrst-degree relatives of patients
with SLE (familial prevalence, 10e12%). Prevalence rates are
higher in monozygotic twins (24e58%) than in dizygotic twins
(2e5%) [1e4].
The major and serious manifestation of SLE is lupus
nephritis (LN). In most patients with SLE, LN is histologically
evident, and kidney biopsy should be considered in any patient
with SLE who has clinical or laboratory evidence of active
nephritis, especially on the ﬁrst episode of nephritis [5].
Many studies suggest that genetic predisposition plays an
important role in the development of both SLE and LN. Multiple
genes, many of which are not yet identiﬁed, mediate this ge-
netic predisposition [1e4,6e9] .
Interleukin (IL)-10 is a cytokine with pleiotropic effects in
immunoregulation and inﬂammation and produced mainly by
monocytes and B lymphocytes [10,11]. IL-10 promotes B-cell-
mediated functions, enhancing survival, proliferation, differ-
entiation, and antibody production [12,13]. It also inhibits T cell
function by suppressing the expression of proinﬂammatory
cytokines such as tumor necrosis factor-a, IL-1, IL-6, IL-8, and
IL-12 [14]. It also inhibits antigen presenting cells by down-
regulating major histocompatibility complex Class II and B7
expression [14e17], which in SLE may contribute to impaired
cell-mediated immunity.
In humans, the IL-10 gene is located on chromosome-1 and
its receptor is located on chromosome 11 [18]. The IL-10 gene
encodes for 5 exons. The IL-10 promoter is highly polymorphic,
and in this region, 2 CA-repeat microsatellites (IL-10.G and IL-
10.R) and 3 single nucleotide polymorphisms (SNPs), at posi-
tions e1082, e819, and e592 from the transcription start site,
have been identiﬁed to correlate with IL-10 production [10].
Haplotypes comprising 3 SNPs at positions e1082, e819, and
e592 have also been found to correlate with IL-10 serum level
[10].
There are several studies suggesting that the IL-10 gene is
associated with SLE susceptibility [19]. Studies in lupus animal
models and humans have shown that anti-IL-10 treatment can
decrease disease activity in terms of clinical features and bio-
logic markers [20e22]. Interestingly, Llorente et al [23]
demonstrated that IL-10 production by monocytes and B cells
in healthy members of families with SLE was signiﬁcantly
higher than that of healthy unrelated controls, but was similar
to that of SLE patients, thus suggesting that a genetically
controlled high innate IL-10 production may predispose to SLE
development [23]. Although there are several studies evalu-
ating the association between IL-10 and SLE, the studies eval-
uating the association between IL-10 and LN are few.
Aim of the study
The aim of this study was to determine the distribution
of the promoter -592 A/C of IL-10 gene in Egyptian patients
with SLE and LN and evaluate the role of the promoter -592
A/C of IL-10 gene in the pathogenesis and clinical and
histopathologic classes of LN.
Methods
This study was conducted on 84 patients with SLE who have
the criteria of Systemic Lupus International Collaborating
Clinics group [24]. Patients were divided into LN group (GroupI, 48 patients with mean age 29.63 ± 8.91 years) and non-LN
group (Group II, 36 patients with mean age 31.81 ± 0.20 years).
The patients of both groups were matched for age, gender, and
ethnic origin. LN was diagnosed clinically by the presence of
persistent proteinuria or hematuria and conﬁrmed by kidney
biopsy. Non-LN patients were diagnosed according to the
criteria of Systemic Lupus International Collaborating Clinics
group [24], including arthritis, skin rash, positive antinuclear
antibodies (ANAs), and positive anti-double-stranded DNA
(dsDNA), but without renal involvement in the form of pro-
teinuria, hematuria, or abnormal renal functions. SLE patients
with proteinuria other than LN as pregnancy and fever or pa-
tients with impaired renal function due to any other cause than
LN as diabetic nephropathy and patients with history of renal
trasnsplantation or hepatitis C virus and hepatitis B virus and
other connective tissue diseases other than SLE were excluded
from the study. All these patients were selected from the
nephrology outpatient clinics in nephrology departement,
Theodor Bilharz Research Institute, Cairo, Egypt. The study was
approved by the appropriate ethics committee and has there-
fore been performed in accordance with Declaration of Hel-
sinki, and written informed consent was obtained from each
patient participated in the study.
Each patient underwent thorough history taking and com-
plete clinical examination.
Peripheral venous blood samples were collected from pa-
tients after proper disinfection.
(1) Two milliliters on EDTA for complete blood count.
(2) Five milliliters of blood in a plain glass tube left to clot at
room temperature for 30 minutes then centrifuged for 10
minutes to obtain serum for chemical and immunological
tests.
Routine examinations included urine analysis, renal func-
tion tests (serum creatinine, urea, sodium, potassium, and uric
acid), complete blood count, erythrocyte sedimentation rate,
and C-reactive protein. Serum C3 and C4, ANA, and anti-dsDNA
were also conducted.
ANA was measured using indirect immunoﬂourescence.
Anti-dsDNA were measured using solid-phase enzyme immu-
noassays kits. C3 and C4 were measured using Nephelometer
(BN ProSpec, Dade Behring, Marburg, Germany).Determination of -592 A/C polymorphisms in the IL-10 gene
promoter
Genomic DNAwas extracted from EDTAewhole blood using
a phenol chloroform extraction method. The -592 A/C poly-
morphism in the IL-10 gene promotor was determined by po-
lymerase chain reaction (PCR) and restriction fragment length
polymorphism protocol using the following designed primer
sequences:
50 TCC AGC CAC AGA AGC TTA CAA C 30 (forward);
50 AGG TCT CTG GGC CTT AGT TTC C 30 (reversed).
PCR was performed on a Gene-Amp PCR System 2700
(Applied Biosystems, Foster City, CA, USA) in the following
conditions: 94C for 5 minutes; 35 cycles of 94C for 30 sec-
onds, 64C for 45 seconds, and 72C for 60 seconds; followed by
a ﬁnal extending step at 72C for 10 minutes. The PCR product
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Rsa I (New England Biolabs, Ipswich, MA, USA). The genotypes
of IL-10 -592 A/C were distinguished by electrophoresis sepa-
ration of the fragments on a 3% agarose gel with 0.1% ethidium
bromide to visualize under ultraviolet light.
IL-10 was determined by enzyme-linked immunosorbent
assay (ELISA) using an ELISA kit (AviBion human IL-10 ELISA kit;
Orgenium Laboratories, Finland) [25]. The mean value of serum
IL-10 levels was compared statistically between LN and non-LN
groups and between LN patients with normal serum creatinine
(20 patients) and LN patients with high serum creatinine (28
patients).
Kidney biopsy was performed for Group I patients and
classiﬁed according to International Society of Nephrology/
Renal Pathology Society [26]. Disease activity was assessed by
SLE disease activity index (SLEDAI) [27], and their correlations
with serum IL-10 and promoter -592 A/C of IL-10 gene were
analyzed.
Statistical analysis
Results were analyzed as means ± SD or number (%). Com-
parison between different parameters in the 2 studied groups
was performed using unpaired 2-tailed Student’s t tests
(GraphPad QuickCalcs). Comparison between categorical data
was performed using Chi-square test. Correlation between
different parameters in the cases group was performed using
Pearson’s correlation (MedCal Statistical Software). Statistical
analysis was performed with the aid of the SPSS computer
program (version 12 windows). The data were considered
signiﬁcant if P < 0.05 and highly signiﬁcant if P < 0.01.
Results
Demographic and clinical characteristics of the studied
groups are shown in Table 1, where there was no statistically
signiﬁcant difference between LN group (Group I) and non-LN
group (Group II) regarding age, gender, duration of the disease,Table 1. Demographic, clinical characteristics, and laboratory parameter
Variable LN group (Group I, n ¼ 48)
Age (y) 29.63 ± 8.91
Sex (female) 41 (85.4)
Duration of disease (y) 6.23 ± 3.00
Edema of lower limb 32 (66.7)
Hypertension 30 (62.5)
Arthritis 29 (60.4)
Skin rash 26 (54.2)
SLEDAI 14.60 ± 8.63
Serum creatinine (mg/dL) 2.45 ± 2.26
Serum urea (mg/dL) 66.05 ± 65.02
24-h urinary protein (mg/d) 2,616.92 ± 2,321.38
Urine analysis
Hematuria 27 (56.3)
Casts 32 (66.7)
CRP (mg/dL) 9.14 ± 8.34
ESR (mm/h) 96.51 ± 29.36
C3 (g/L) 0.75 ± 0.52
C4 (g/L) 0.23 ± 0.44
ANA (<1:20) 1/620
Anti-dsDNA (IU/mL) 174.11 ± 149.52
Serum IL-10 (pg/mL) 21.13 ± 14.17
Data are presented as mean ± SD or number (%).
*P < 0.05, signiﬁcant; **P < 0.01, highly signiﬁcant.
ANA, antinuclear antibodies; CRP, C-reactive protein; dsDNA, double-strand
nephritis; SLEDAI, systemic lupus erythematosus disease activity index.arthritis, and skin rash, whereas edema of lower limbs and
hypertention were statistically signiﬁcantly high in Group I
compared with Group II (P ¼ 0.001).
Laboratory parameters of the studied groups are also shown
in Table 1, where there was a statistically signiﬁcant increase in
anti-dsDNA, in Group I (174.11 ± 149.52 IU/mL) compared with
Group II (58.21 ± 23.47 IU/mL, P ¼ 0.001). On the other hand,
there was a statistically signiﬁcant decrease in C3 (P ¼ 0.001)
and C4 (P ¼ 0.001) in Group I compared with Group II.
There was a statistically signiﬁcant increase in the mean
value of SLEDAI in Group I (14.60 ± 8.63) compared with Group
II (10.17 ± 3.11, P ¼ 0.003).
There was a statistically signiﬁcant increase in the mean
value of serum IL-10 in Group I (21.13 ± 14.17 pg/mL) compared
with Group II (4.96 ± 3.81 pg/mL, P ¼ 0.001). There was no
statistically signiﬁcant difference in the mean value of serum
IL-10 in LN patients with high serum creatinine compared with
LN patients with normal serum creatinine (23.11 ± 16.15 vs.
19.15 ± 12.19, P ¼ 0.361).
There was a statistically signiﬁcant negative correlation
between serum IL-10 level and serum C3 (r ¼ e0.512, P ¼
0.024), and a statistically signiﬁcant positive correlation be-
tween serum IL-10 and SLEDAI (r ¼ 0.466, P ¼ 0.001; Fig. 1) in
LN group.
There were no statistically signiﬁcant differences in the
distribution of the -592 A/C genotypes in IL-10 gene promoter
or the allele frequencies between Groups I and II (Table 2).
There was no statistically signiﬁcant difference between AC/
CC and AA genotypes with different clinical and laboratory
parameters in Group I (Table 3).
Renal pathology data
Fourteen patients (29.16%) were classiﬁed as focal prolifer-
ative glomerulonephritis (Class III LN), 18 patients (37.5%) were
classiﬁed as diffuse proliferative glomerulonephritis (Class IV
LN), 8 patients (16.7%) were classiﬁed as membranous ne-
phropathy (Class V LN), 4 patients (8.3%) were classiﬁed as Classs of the studied groups
Non-LN group (Group II, n ¼ 36) P
31.81 ± 0.20 0.147
30 (83.3) 0.865
5.30 ± 1.83 0.104
0 0.001**
0 0.001**
19 (52.8) 0.824
17 (47.2) 0.891
10.17 ± 3.11 0.003*
0.80 ± 0.15 0.001**
29.30 ± 9.08 0.001**
131.876 ± 0.13 0.001**
0 0.001**
0 0.001**
8.23 ± 7.13 0.600
63.11 ± 38.79 0.001**
1.23 ± 0.21 0.001**
0.74 ± 0.57 0.001**
1/80 0.001**
58.21 ± 23.47 0.001**
4.96 ± 3.81 0.001**
ed DNA; ESR, erythrocyte sedimentation rate; IL, interleukin; LN, lupus
Figure 1. Correlation between IL-10 (pg/mL) and SLEDAI (r ¼ 0.466, P ¼
0.001).
IL, interleukin; SLEDAI, systemic lupus erythematosus disease activity
index.
Table 2. Distribution of the IL-10 gene promoter -592 A/C poly-
morphisms and allele frequency in the 2 studied groups
A/C polymorphism LN group
(Group I, n ¼ 48)
Non-LN group
(Group II, n ¼ 36)
P
AA (n ¼ 12) 8 (16.7) 4 (11.1) 0.546
AC (n ¼ 38) 22 (45.8) 16 (44.4) 0.807
CC (n ¼ 34) 18 (37.5) 16 (44.4) 0.953
Alleles Group 1 (n ¼ 90) Group 2 (n ¼ 58)
A (n ¼ 52) 36 (40.0) 16 (27.6) 0.585
C (n ¼ 96) 54 (60.0) 42 (72.4) 0.293
Data are presented as number (%).
IL, interleukin; LN, lupus nephritis.
Table 3. Clinical and laboratory parameters in lupus nephritis
patients with different genotypes
Variables AA (n ¼ 8) AC þ CC (n ¼ 40) P
24-h urinary
protein (mg/d)
1,592 ± 1,238 2,783 ± 2,412 0.183
Urinary cast 4 (50) 24 (60.0) 0.863
Urinary RBCs 4 (50) 16 (40.0) 0.839
SLEDAI 11.34 ± 5.13 12.14 ± 8.26 0.794
Anti-dsDNA 171.65 ± 122.11 173.48 ± 151.21 0.975
Serum IL-10
(pg/mL)
16.15 ± 5.65 23.51 ± 15.48 0.194
Data are presented as mean ± SD or number (%).
dsDNA, double-stranded DNA; IL, interleukin; RBC, red blood cell;
SLEDAI, systemic lupus erythematosus disease activity index.
Table 4. Comparison between AC and CC genotypes in different
pathologic classes of lupus nephritis
Class III
(n ¼ 14)
Class IV
(n ¼ 18)
Class V
(n ¼ 8)
P
AC (n ¼ 22) 9 (64.3) 8 (44.4) 5 (62.5) 0.074
CC (n ¼ 18) 5 (35.7) 10 (55.5) 3 (37.5) 0.285
Data are presented as numbers (%).
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glomerulonephritis (Class VI LN).
There was no statistically signiﬁcant difference between AC
and CC genotypes with different pathologic classes of LN (AA
was not included due to its small number; Table 4).
Discussion
IL-10 gene polymorphisms and increased IL-10 production
have been suggested to play a role in susceptibility or exacer-
bating of SLE [28,29].
Although LN is one of the major and serious manifestations
of SLE, there have been few studies to evaluate the association
between IL-10 and LN [16]. In this exploratory study, we eval-
uated the association of IL-10 and IL-10 gene promoter -592 A/C
with LN susceptibility, activity, and histopathologic classes of
LN.
The present study showed that serum IL-10 was statistically
signiﬁcantly high in the LN group compared with non-LN
group, and there was a positive correlation between IL-10 and
SLEDAI and a negative correlation between IL-10 and C3 in LN
group. These results are in agreement with the results that are
showed by Lit et al [30] and Park et al [31]. The results of Lit et al
and Park et al and our results indicate that dysregulation and
high levels of IL-10 may play an important role in the patho-
genesis and development of LN.
However, the present study found that there was no statis-
tically signiﬁcant difference in the distribution of the IL-10 gene
promoter -592 A/C genotypes between LN patients and non-LN
patients suggesting that the -592 A/C polymorphism in the IL-
10 gene promoter may not be associated with LN susceptibility
and this is similar to the results revealed by Zhu et al [32]. In
contrast to our results, in the Hong Kong Chinese population,
therewas a signiﬁcant difference in the distribution of the IL-10
gene promoter -592 A/C genotypes between SLE patients with
and without renal involvement [33]. These different ﬁndings
may be explained by the presence of a signiﬁcant racial varia-
tion in the distribution of the -592 A/C polymorphism in the IL-
10 gene promoter.In addition, this study showed that there was no statistically
signiﬁcant difference in the level of IL-10 in AC/CC genotypes
compared with AA genotype which is similar to the results
showed by Zhu et al [32]. In addition, present study found
that there was no statistically signiﬁcant increase in SLEDAI,
anti-dsDNA, proteiuria, hematuria, and urinary casts in AC/CC
genotypes compared with AA genotype. In opposition to
our results, Zhu et al noted that patients with AC/CC
genotypes showed statistically signiﬁcant increase in SLEDAI,
anti-dsDNA, proteiuria, hematuria, and casts comparedwith AA
genotype patients.
As regard the association of the IL-10 gene promoter -592
A/C polymorphism with different pathologic classes of LN, the
present study showed that there was no statistically signiﬁ-
cant difference in the distribution of AC and CC genotypes (AA
was not included because of its small number) among
different classes of LN (III, IV, and V). However, Zhu et al
[32] showed that patients with Class IV LN had a higher
frequency of AC/CC genotypes than those with Class V LN
suggesting that the IL-10 gene promoter -592 A/C poly-
morphism may play a role in diverse renal pathologic changes
in LN patients and that those carrying a higher frequency of
AC/CC genotypes were more likely to have diffuse proliferative
lesions in the kidney.
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morphism not associated with serum IL-10 level may have an
impact on renal lesions of LN. One study showed that the 592 C
allele was associated with a higher frequency of positive anti-
dsDNA, which have been considered to be responsible for the
initiation of LN [32]. This is in opposition to our results as -592 C
allele was not associated with a higher frequency of positive
anti-dsDNA. IL-10 gene polymorphism might possibly impact
on the local IL-10 level in the glomeruli, other than the serum
IL-10 level, that could be responsible for the renal lesions in LN
and the difference among different pathologic classes [34].
It is also possible that the promoter -592 A/C of IL-10 gene
may act indirectly through linkages with some other single
nucleotide polymorphisms in IL-10 gene promoter at positions
e1082 and e819 that have been identiﬁed to correlate with IL-
10 production [10]. Haplotypes comprising SNPs at positions
e1082 and e819 have also been found to correlate with IL-10
serum level [10]. In addition, SNPs at positions e1082 and
e819 have been identiﬁed to play a role in the
pathologic lesions in the lupus nephritis [32].
This study has some limitations such as small samples of
patients, no pathologic data for Group II and there is no follow-
up for both groups of patients. So we need larger studies with a
follow-up of the patients to detect the treatment response and
its effect on the serum levels of IL-10.
In conclusion, IL-10 suggested to play a role in pathogenesis
and development of LN. However, the promoter -592 A/C of IL-
10 gene suggested to be not associated with serum IL-10 levels
or LN susceptibility. In addition, it appears that the promoter
-592 A/C of IL-10 gene is not associated with LN activity or the
pathologic classes of LN.Conﬂicts of interest
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